Press Announcements > FDA expands treatment window for use of clot retrieval devices in certain stroke patients

Press Announcements > FDA expands treatment window for use of clot retrieval devices in certain stroke patients





FDA expands treatment window for use of clot retrieval devices in certain stroke patients

The U.S. Food and Drug Administration today cleared the use of the Trevo clot retrieval device to treat certain stroke patients up to 24 hours after symptom onset, expanding the device’s indication to a broader group of patients. This device is cleared for use as an initial therapy for strokes due to blood clots (also known as an acute ischemic stroke) to reduce paralysis, speech difficulties and other stroke disabilities and only as an addition to treatment with a medication that dissolves blood blots called tissue plasminogen activator (t-PA). The device was previously cleared for use in patients six hours after symptom onset. Continue reading.